DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
-5.76%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$4.49B
AUM Growth
+$4.49B
(-7.1%)
Cap. Flow
+$226M
Cap. Flow
% of AUM
5.04%
Top 10 Holdings %
Top 10 Hldgs %
44.77%
Holding
120
New
16
Increased
17
Reduced
12
Closed
11
Top Buys
| 1 |
Catalyst Pharmaceutical
CPRX
|
$74.1M |
| 2 |
Viatris
VTRS
|
$66.7M |
| 3 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
$44.3M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$39.7M |
| 5 |
Owens & Minor
OMI
|
$39.1M |
Top Sells
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$46.7M |
| 2 |
Phreesia
PHR
|
$44.2M |
| 3 |
IMGN
Immunogen Inc
IMGN
|
$31.5M |
| 4 |
RAIN
Rain Oncology Inc. Common Stock
RAIN
|
$22.5M |
| 5 |
Amylyx Pharmaceuticals
AMLX
|
$20.8M |
Sector Composition
| 1 | Healthcare | 62.79% |
| 2 | Financials | 0.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Kura Oncology
KURA
$732M
| $29.1M | 0.65% |
2,383,000
| – | – |
|
27
Pulmonx
LUNG
$67.6M
| $26.9M | 0.6% |
+2,402,704
| New | +$26.9M |
|
28
DocGo
DCGO
$152M
| $26.5M | 0.59% |
+3,059,000
| New | +$26.5M |
|
29
Edgewise Therapeutics
EWTX
$1.54B
| $26.2M | 0.58% |
3,933,137
| – | – |
|
|
BLU
30
DELISTED
BELLUS Health Inc.
BLU
| $25.8M | 0.57% |
3,581,000
| – | – |
|
31
Krystal Biotech
KRYS
$4.35B
| $25M | 0.56% |
311,949
+136,949
| +78% | +$11M |
|
32
Terns Pharmaceuticals
TERN
$651M
| $24.4M | 0.54% |
2,059,421
-791,866
| -28% | -$9.38M |
|
33
IDEAYA Biosciences
IDYA
$2.26B
| $23.9M | 0.53% |
1,743,628
| – | – |
|
34
BioCryst Pharmaceuticals
BCRX
$1.74B
| $23.1M | 0.51% |
+2,765,000
| New | +$23.1M |
|
35
GeneDx Holdings
WGS
$3.65B
| $20.9M | 0.47% |
57,192,101
+47,142,857
| +469% | +$17.2M |
|
36
Ventyx Biosciences
VTYX
$184M
| $20.7M | 0.46% |
+617,000
| New | +$20.7M |
|
|
VIGL
37
DELISTED
Vigil Neuroscience
VIGL
| $20.1M | 0.45% |
2,052,010
| – | – |
|
38
Viking Therapeutics
VKTX
$3.02B
| $18.7M | 0.42% |
+1,125,000
| New | +$18.7M |
|
39
Guardant Health
GH
$8.11B
| $18.3M | 0.41% |
+778,999
| New | +$18.3M |
|
40
Revolution Medicines
RVMD
$7.43B
| $18M | 0.4% |
829,737
-61,850
| -7% | -$1.34M |
|
41
Alphatec Holdings
ATEC
$2.35B
| $16.3M | 0.36% |
1,046,791
| – | – |
|
|
DALS
42
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
| $16.2M | 0.36% |
1,600,000
| – | – |
|
43
Tarsus Pharmaceuticals
TARS
$2.44B
| $14.5M | 0.32% |
1,156,032
-168,182
| -13% | -$2.11M |
|
44
Denali Therapeutics
DNLI
$2.24B
| $13.7M | 0.31% |
594,989
-205,011
| -26% | -$4.72M |
|
45
AnaptysBio
ANAB
$630M
| $13.3M | 0.3% |
613,000
-548,826
| -47% | -$11.9M |
|
46
Roivant Sciences
ROIV
$8.6B
| $12.9M | 0.29% |
+1,750,000
| New | +$12.9M |
|
|
NVTA
47
DELISTED
Invitae Corporation
NVTA
| $12.5M | 0.28% |
+9,274,707
| New | +$12.5M |
|
48
Mineralys Therapeutics
MLYS
$1.94B
| $11.4M | 0.25% |
+729,021
| New | +$11.4M |
|
49
Insmed
INSM
$30.3B
| $11.2M | 0.25% |
658,546
-5,600
| -0.8% | -$95.5K |
|
50
Iovance Biotherapeutics
IOVA
$800M
| $11.2M | 0.25% |
+1,831,607
| New | +$11.2M |
|